Editorial: Therapeutic Drug Monitoring of Infliximab During Induction Therapy in IBD —Is This the Time for Model Informed Precision Dosing?
Alimentary Pharmacology & Therapeutics · 04.11.2026
DOI: 10.1111/apt.71087 ↗Kurz gefasst
Editorial in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 04.11.2026. Verfasst von Benjamin Mecsas-Faxon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachus…. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Konstantinos Papamichael, Adam S Cheifetz
Zitieren
APA
Mecsas-Faxon, B., Papamichael, K., & Cheifetz, A. S. (2026). Editorial: Therapeutic Drug Monitoring of Infliximab During Induction Therapy in IBD —Is This the Time for Model Informed Precision Dosing?. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71087
Vancouver
Mecsas-Faxon B, Papamichael K, Cheifetz AS. Editorial: Therapeutic Drug Monitoring of Infliximab During Induction Therapy in IBD —Is This the Time for Model Informed Precision Dosing?. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71087
BibTeX
@article{MecsasFaxon2026,
author = {Mecsas-Faxon, Benjamin and Papamichael, Konstantinos and Cheifetz, Adam S},
title = {Editorial: Therapeutic Drug Monitoring of Infliximab During Induction Therapy in IBD —Is This the Time for Model Informed Precision Dosing?},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.71087}
}
EUVIMED